Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 (Q27649718)

2

0 references

D Lawrence

3

0 references

S Marsters

4

0 references

R Pitti

5

0 references

S Yee

6

0 references

S Ross

7

0 references

L Deforge

8

0 references

H Koeppen

9

0 references

M Sagolla

10

0 references

D Compaan

11

0 references

H Lowman

12

0 references

S Hymowitz

13

0 references

A Ashkenazi

Cell Death & Differentiation

14

0 references

language of work or name

1 reference

April 2008

0 references

published in

0 references

volume

15

0 references

issue

4

0 references

page(s)

751-61

0 references

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

Apoptosis by death factor

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

Death receptors: signaling and modulation

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

Death and anti-death: tumour resistance to apoptosis

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

A novel receptor for Apo2L/TRAIL contains a truncated death domain

20 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.CDD.4402306

20 April 2017

Caspases: enemies within

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

The Bcl2 family: regulators of the cellular life-or-death switch

20 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

IAP proteins: blocking the road to death's door

20 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Estimates of the cancer incidence and mortality in Europe in 2006.

20 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Targeted therapies for cancer 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Promoting apoptosis as a strategy for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Cell death: critical control points

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Intrinsic tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

The machinery of programmed cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

The role of the Bcl-2 protein family in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Apo2L/TRAIL and its death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Targeting death receptors in cancer with Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Death-receptor activation halts clathrin-dependent endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

TRAIL receptor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Rapid and efficient site-specific mutagenesis without phenotypic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

Targeting apoptosis pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

7 January 2021

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

7 January 2021

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4402306

7 January 2021

Identifiers

DOI

10.1038/SJ.CDD.4402306

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

608750

1019980757

0 references

608750

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference